Vest Financial LLC Sells 3,946 Shares of AbbVie Inc. $ABBV

Vest Financial LLC lowered its stake in AbbVie Inc. (NYSE:ABBV) by 1.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 268,319 shares of the company’s stock after selling 3,946 shares during the period. Vest Financial LLC’s holdings in AbbVie were worth $67,520,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ABBV. Norges Bank bought a new stake in shares of AbbVie during the fourth quarter worth $5,865,055,000. Wellington Management Group LLP lifted its stake in shares of AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after acquiring an additional 8,646,424 shares during the period. Capital World Investors boosted its holdings in AbbVie by 106.3% in the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after acquiring an additional 6,736,161 shares during the last quarter. Cardano Risk Management B.V. boosted its holdings in AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after acquiring an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by company insiders.

AbbVie Price Performance

Shares of ABBV stock opened at $265.63 on Thursday. The stock has a market cap of $469.31 billion, a PE ratio of 75.04, a price-to-earnings-growth ratio of 0.86 and a beta of 0.30. The stock has a 50-day moving average of $246.98 and a 200-day moving average of $226.95. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 14.07 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie’s payout ratio is 195.48%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ABBV. Citigroup upped their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Royal Bank Of Canada lifted their price target on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research report on Friday, July 10th. Evercore set a $235.00 price objective on shares of AbbVie in a report on Friday, May 15th. BNP Paribas Exane raised their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Finally, Wells Fargo & Company lifted their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $275.73.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie completed a multibillion-dollar senior notes offering to help finance its acquisition of Apogee Therapeutics. The transaction provides funding for the deal and supports AbbVie’s strategy of expanding its immunology and specialty medicines portfolio as it seeks new growth opportunities. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition AbbVie Raises $9 Billion Debt to Fund Acquisition
• Neutral Sentiment: The Apogee financing also introduces additional leverage. While debt allows AbbVie to pursue the acquisition without issuing equity, investors will assess the impact of higher interest costs and whether Apogee’s pipeline generates sufficient returns to justify the transaction. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition
• Neutral Sentiment: AbbVie announced its 2026 Immunology Scholarship recipients, continuing a 10-year community-support program. The announcement reinforces corporate reputation but is unlikely to materially affect earnings or the stock’s near-term valuation. AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients
• Negative Sentiment: Executive Vice President Nicholas Donoghoe sold 32,710 ABBV shares for approximately $8.18 million, reducing his holdings by about 30.5%. Insider sales can reflect personal financial planning, but the sizable transaction may create a modest negative sentiment signal for investors. AbbVie Insider Transaction

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.